Literature DB >> 12451609

Extensor digitorum brevis test and resistance to botulinum toxin type A.

Paul H Gordon1, Clifton L Gooch, Paul E Greene.   

Abstract

We studied 22 patients with dystonia to determine the normal range of values for the extensor digitorum brevis (EDB) test, and to determine its sensitivity and specificity in detecting resistance to botulinum toxin type A (BTX-A). Three compound muscle action potentials (CMAPs) elicited by peroneal nerve stimulation were averaged before and 2 weeks after injection of 20 units of BTX-A into the EDB. Amplitude and area ratios were calculated by dividing the averaged postinjection CMAP by the averaged preinjection CMAP values. The difference in means of this ratio between clinically sensitive and resistant subjects was statistically significant (P < 0.002). A normal range of <0.45 for each ratio was determined by adding two standard deviations to the ratio mean of 14 clinically sensitive subjects. Four of five resistant patients had values outside the normal range. The EDB test is a simple quantitative method of detecting resistance to BTX-A, with a sensitivity of 80% and specificity of 94%. Copyright 2002 Wiley Periodicals, Inc. Muscle Nerve 26: 828-831, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12451609     DOI: 10.1002/mus.10231

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

Review 1.  [Botulinum toxin in urology. Indications and results].

Authors:  B Schurch; A Reitz
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

2.  Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia.

Authors:  Joaquim J Ferreira; Roongroj Bhidayasiri; Carlo Colosimo; Maria Jose Marti; Benjamin Zakine; Pascal Maisonobe
Journal:  Funct Neurol       Date:  2012 Oct-Dec

3.  [Proof of botulinum toxin antibodies with the Extensor Digitorum Brevis Test].

Authors:  A Bachhuber; A Wagner; G Reichel; M Doberenz; A Stenner; W Hermann
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

4.  Responsiveness to botulinum toxin type A in muscles of complex regional pain patients with tonic dystonia.

Authors:  Johanna C M Schilder; J Gert van Dijk; Dirk Dressler; Johannes H T M Koelman; Johan Marinus; Jacobus J van Hilten
Journal:  J Neural Transm (Vienna)       Date:  2014-02-15       Impact factor: 3.575

5.  The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm.

Authors:  Marcello Esposito; A Fasano; C Crisci; R Dubbioso; R Iodice; Lucio Santoro
Journal:  Neurol Sci       Date:  2013-08-15       Impact factor: 3.307

6.  Botulinum Toxin A Treatment in HIV Infected Patients-A Long-Term Observational Study.

Authors:  Stefan Evers; Alexandra Buchheister; Doris Reichelt; Ingo W Husstedt; Achim Frese
Journal:  J Clin Med       Date:  2022-04-14       Impact factor: 4.241

Review 7.  Immunogenicity Associated with Botulinum Toxin Treatment.

Authors:  Steven Bellows; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2019-08-26       Impact factor: 4.546

8.  Immunogenicity of botulinum toxin.

Authors:  Syeo Young Wee; Eun Soo Park
Journal:  Arch Plast Surg       Date:  2022-01-15

9.  Effect of the refrigerator storage time on the potency of botox for human extensor digitorum brevis muscle paralysis.

Authors:  Mee Young Park; Ki Young Ahn
Journal:  J Clin Neurol       Date:  2013-07-01       Impact factor: 3.077

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.